APIXABAN TEVA
2,5MG TBL FLM 180 II
| SÚKL code | 0239396 |
|---|---|
| Name of the product | APIXABAN TEVA |
| _MA_MEDICATION_DETAIL_INFO_MED_NAME i | APIXABAN TEVA |
| Supplement | 2,5MG TBL FLM 180 II |
| Strenght | 2,5MG |
| Pharmaceutical form | Film-coated tablet |
| Package | 180 II |
| Route | Oral use |
| Language of the pack | Czech |
| Wrap type | Tablet container |
| Legal status | na lékařský předpis |
| Active substance | APIXABAN (APIXABANUM) |
| ATC group | B01AF02 |
| ATC group name | APIXABAN |
Marketing authorisation information
| Registration Number | 16/ 217/19-C |
|---|---|
| Type of MA | A mutual recognition procedure (MRP, DCP), where CZ is Concerned member state |
| MA status | B - medicinal product after change, may be placed on the market for the period of 6 months (Placed on the market till) and used until expiration, not later than till the end of validity of the marketing authorisation (Valid till) |
| Placed on the market till | 30. 11. 2021 |
| MA Holder | Teva B.V., Haarlem |
| MA Holder country | NIZOZEMSKO |
| Actual MA holder | Teva Pharmaceuticals CR, s.r.o., Praha |
| Actual MA holder country | ČESKÁ REPUBLIKA |
cz